- Home
- PIPR vs TERN Comparison
PIPR vs TERN Comparison
Compare PIPR & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PIPR | TERN |
|---|---|---|
| Founded | 1895 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 4.8B |
| IPO Year | 2003 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PIPR | TERN |
|---|---|---|
| Price | $88.84 | $52.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $91.38 | $46.49 |
| AVG Volume (30 Days) | 559.8K | ★ 10.8M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.14% | N/A |
| EPS Growth | ★ 54.49 | 8.04 |
| EPS | ★ 15.82 | N/A |
| Revenue | ★ $1,904,217,000.00 | N/A |
| Revenue This Year | $12.30 | N/A |
| Revenue Next Year | $13.55 | N/A |
| P/E Ratio | $5.75 | ★ N/A |
| Revenue Growth | ★ 24.33 | N/A |
| 52 Week Low | $72.48 | $2.81 |
| 52 Week High | $380.26 | $53.19 |
Technical Indicators
Market Signals| Indicator | PIPR | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 21.71 | 73.99 |
| Support Level | $72.48 | $52.42 |
| Resistance Level | $341.25 | $53.19 |
| Average True Range (ATR) | 2.53 | 0.13 |
| MACD | 9.15 | -0.41 |
| Stochastic Oscillator | 78.62 | 92.22 |
Price Performance
Historical ComparisonAbout PIPR Piper Sandler Companies
Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services followed by Equity financing.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.